Page 292 - medicina-integrativa_compress

288 PARTE II, SECCIÓN 4 ENFERMEDADES CARDIOVASCULARES

8. Masoudi FA, Havranek EP, Krumholz HM: The burden of chronic 33. Ondarroa M, Quinn P: Proton magnetic resonance spectroscopic
congestive heart failure in older persons: Magnitude and implications studies of the interaction of ubiquinone-10 with phospholipid
for policy and research. Heart Fail Rev 7:9-16, 2002. membranes. Int J Biochem 155:353, 1986.
9. Hunt SA, Abraham WT, Chin MH, et al: ACC/AHA 2005 guideline 34. Folkers K, Vadhanavikit S, Mortensen SA: Biochemical rationale and
update for the diagnosis and management of chronic heart failure in myocardial tissue data on the effective therapy of cardiomyopathy
the adult—summary article: A report of the American College of with coenzyme Q 10 . Proc Natl Acad Sci U S A 82:901-904, 1985.
Cardiology/American Heart Association Task Force on practice 35. Littarru GP, Ho L, Folkers K: Deficiency of coenzyme Q 10 in human
guidelines (writing committee to update the 2001 guidelines for the heart disease: II. Int J Vitam Nutr Res 42:413-434, 1972.
evaluation and management of heart failure). J Am Coll Cardiol 36. Mortensen SA, Kondrup J, Folkers K: Myocardial deficiency of
46:1116-1143, 2005. Available at coenzyme Q 10 and carnitine in cardiomyopathy: Biochemical
http://www.acc.org/clinical/guidelines/failure//index.pdf. Accessed rationale for concomitant coenzyme Q 10 and carnitine
December 18, 2005. supplementation. In Folkers K, Littarru GP, Yamagami T (eds):
10. Zevitz ME: Heart failure. Available at http://www.emedicine.com/ Biomedical and Clinical Aspects of CoEnzyme Q 10 , Vol 6.
med/topic3552.htm. Amsterdam, Elsevier, 1991, pp. 269-281.
11. Young JB: Contemporary management of patients with heart failure. 37. Mortensen SA: Endomyocardial biopsy: technical aspects and
Med Clin North Am 79:1171-1190, 1995. indications. Dan Med Bull 36:507-532, 1989.
12. Packer M: How should physicians view heart failure? The 38. Mortensen SA, Vadhanavikit S, Folkers K: Deficiency of coenzyme
philosophical and physiological evolution of three conceptual models Q 10 in myocardial failure. Drugs Exp Clin Res 10:497-502, 1984.
of the disease. Am J Cardiol 71(Suppl):3C-11C, 1993. 39. Kitamura N, et al: Myocardial tissue level of coenzyme Q 10 in patients
13. Francis GS, Goldsmith SR, Levine TB, et al: The neurohormonal axis with cardiac failure. In Folkers K, Yamamura Y (eds): Biomedical and
in congestive heart failure. Ann Intern Med 101:370-377, 1984. Clinical Aspects of Coenzyme Q, Vol 4. Amsterdam, Elsevier, 1984,
14. Packer M: The neurohormonal hypothesis: A theory to explain the pp 243-252.
mechanism of disease progression in heart failure. J Am Coll Cardiol 40. Mortensen SA: Perspectives on therapy of cardiovascular disease with
20:248-254, 1992. coenzyme Q 10 . Clin Invest 71:116-123, 1993.
15. Graham JDP: Crataegus oxycantha in hypertension. BMJ Nov 11:951, 41. Langsjoen PH, Vadhanavikit S, Folkers K: Response of patients in
1939. classes III and IV of cardiomyopathy to therapy in a blind and
16. Busse W: Standardized Crataegus extract clinical monograph. Q Rev crossover trial with coenzyme Q 10 . Proc Natl Acad Sci U S A 82:
Nat Med Fall:189-197, 1996. 4240-4244, 1985.
17. Schussler M, Holzl J, Fricke U: Myocardial effects of flavonoids from 42. Yamamura Y, Ishiyama T, Yamagami T, et al: Clinical use of
Crataegus species. Arzneimittelforschung 45:842-845, 1995. coenzyme Q for treatment of cardiovascular disease. Jpn Circ J
18. Weihmayr T, Ernst E: Therapeutic effectiveness of Crataegus. 31:168, 1967.
Fortschr Med 114:27-29, 1996. 43. Langsjoen PH, Langsjoen PH, Folkers K: Long-term efficacy and
19. Pittler MH, Schmidt K, Ernst E: Hawthorn extract for treating safety of coenzyme Q 10 therapy for idiopathic dilated
chronic heart failure: Meta-analysis of randomized trials. Am J Med cardiomyopathy. Am J Cardiol 65:521-523, 1990.
114:665-674, 2003. 44. Judy WV, et al: Double-blind double-crossover study of coenzyme
20. Tauchert M, Ploch M, Hübner W-D: Effectiveness of hawthorn Q 10 in heart failure. In Folkers K, Yamamura Y (eds): Biomedical and
extract LI 132 compared with the ACE inhibitor captopril: Multicenter Clinical Aspects of Coenzyme Q, Vol 5. Amsterdam, Elsevier, 1986,
double-blind study with 132 NYHA stage II patients. Munch Med pp 315-322.
136(Suppl 1):S27-S33, 1994. 45. Langsjoen PH, Langsjoen AM: Overview of the use of CoQ 10 in
21. Schmidt U, Kuhn U, Ploch M, et al: Efficacy of the hawthorn cardiovascular disease. Biofactors 9:273-284, 1999.
(Crataegus) preparation LI 132 in 78 patients with chronic congestive 46. Soja AM, Mortensen SA: Treatment of congestive heart failure with
heart failure defined as NYHA functional class II. Phytomedicine coenzyme Q 10 illuminated by meta-analyses of clinical trials. Mol
1:17-24, 1994. Aspects Med 18(Suppl):S159-S168, 1997.
22. Weikl A, Assmus KD, Neukum-Schmidt A, et al: Crataegus special 47. Morisco C, Trimarco B, Condorelli M: Effect of coenzyme
extract WS 1442: Assessment of objective effectiveness in patients Q 10 therapy in patients with congestive heart failure: A long-term
with heart failure. Fortschr Med 114:291-296, 1996. multicenter randomized study. Clin Invest 71(Suppl):S34-S36,
23. Leuchtgens H: Crataegus special extract WS 1442 in NYHA II heart 1993.
failure: A placebo-controlled randomized double-blind study. 48. Baggio E, Gandini R, Plancher AC, et al: Italian multicenter study on
Fortschr Med 111:352-354, 1993. the safety and efficacy of coenzyme Q 10 as adjunctive therapy in heart
24. Tauchert M, Gildor A, Lipinski J: High-dose Crataegus extract WS failure. Mol Aspects Med 15:287-294, 1994.
1442 in the treatment of NYHA stage II heart failure. Herz 24: 49. Langsjoen PH, Langsjoen AM: Coenzyme Q 10 in cardiovascular
465-474, 1999. disease with emphasis on heart failure and myocardial ischemia. Asia
25. Degenring FH, Suter A, Weber M, Saller R: A randomised double- Pac Heart J 7:160-168, 1998.
blind placebo-controlled clinical trial of a standardised extract of 50. Judy WV, Hall JH, Folkers K: Coenzyme Q 10 withdrawal: Clinical
fresh Crataegus berries (Crataegisan) in the treatment of patients with relapse in congestive heart failure patients. In Folkers K, Littaru GP,
congestive heart failure NYHA II. Phytomedicine 10:363-369, 2003. Yamagami T (eds): Biomedical and Clinical Aspects of Coenzyme Q.
26. Tankanow R, Tamer HR, Streetman DS, et al: Interaction study Amsterdam, Elsevier, 1991, pp 283-298.
between digoxin and a preparation of hawthorn (Crataegus 51. Langsjoen PH, Folkers K, Lyson K, et al: Pronounced increase of
oxyacantha). J Clin Pharmacol 43:637-642, 2003. survival of patients with cardiomyopathy when treated with coenzyme
27. Bagchi D: A review of the clinical benefits of coenzyme Q 10 . J Adv Q 10 and conventional therapy. Int J Tissue React 12:163-168, 1990.
Med 10:139-148, 1997. 52. Judy WV, Folkers K, Hall JH: Improved long-term survival in
28. Nayler WG: The use of coenzyme Q 10 to protect ischaemic heart coenzyme Q 10 -treated chronic heart failure patients compared to
muscle. In Yamamura Y, Folkers K, Ito Y (eds): Biomedical and conventionally treated patients. In Folkers K, Littarru GP, Yamagami
Clinical Aspects of Coenzyme Q, Vol 2. Amsterdam, Elsevier, T (eds): Biomedical and Clinical Aspects of Coenzyme Q, Vol 4.
1980, pp 409-425. Amsterdam, Elsevier, 1991, pp 291-298.
29. Awata N, et al: The effects of coenzyme Q 10 on ischemic heart disease 53. Watson PS, Scalia GM, Galbraith A, et al: Lack of effect of coenzyme
evaluated by dynamic exercise test. In Yamamura Y, Folkers K, Ito Q 10 on left ventricular function in patients with congestive heart
Y (eds): Biochemical and Clinical Aspects of Coenzyme Q 10 , Vol 2. failure. J Am Coll Cardiol 33:1549-1552, 1999.
Amsterdam, Elsevier, 1980, pp 247-254. 54. Khatta M, Alexander BS, Krichten CM, et al: The effect of coenzyme
30. Nakamura Y, Takahashi M, Hayashi J, et al: Protection of ischaemic Q 10 in patients with congestive heart failure. Ann Intern Med
myocardium with coenzyme Q 10 . Cardiovasc Res 16:132-137, 1982. 132:636-640, 2000.
31. Crane FL, Navas P: The diversity of coenzyme Q function. Mol 55. Chopra RK, Goldman R, Sinatra ST, et al: Relative bioavailability of
Aspects Med 18(Suppl):S1-S6, 1997. coenzyme Q 10 formulations in human subjects. Int J Vitam Nutr Res
32. Frei B, Kim MC, Ames BN: Ubiquinol-10 is an effective lipid-soluble 68:109-113, 1998.
antioxidant at physiological concentrations. Proc Natl Acad Sci U S A 56. Greenberg S, Frishman WH: Co-enzyme Q 10 : A new drug for
87:4879-4883, 1990. cardiovascular disease. J Clin Pharmacol 30:596-608, 1990.